Pharmaceuticals

Next Generation Tissue Biomarkers Market Forecast 2025–2034: Where Businesses Should Invest Next

November 20, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Predicted Market Size Trajectory For The Next Generation Tissue Biomarkers Market From 2025 To 2034?

The next generation tissue biomarkers market has seen rapid growth in recent years. It is forecast to increase from $2.68 billion in 2024 to $3.03 billion in 2025, at a compound annual growth rate (CAGR) of 13.1%. This historic growth can be ascribed to factors such as the escalating demand for personalized medicine, the expanding use of immunohistochemistry techniques, the increasing requirement for early disease detection, rising healthcare expenditures, advancements in diagnostic imaging technologies, heightened awareness about biomarker-based diagnostics, and a strengthened focus on companion diagnostics.

The next generation tissue biomarkers market size is anticipated to experience swift expansion in the coming years. It is projected to grow to $4.89 billion in 2029, demonstrating a compound annual growth rate (CAGR) of 12.7%. This growth during the forecast period can be attributed to an escalating demand for multiplex biomarker assays, the increasing utilization of next-generation sequencing, rising investments in cancer research, the expanding applications of digital pathology, the growing deployment of AI in diagnostics, a significant increase in clinical trials for targeted therapies, and the growing availability of tissue-based genomic data. Prominent trends within this forecast period include advancements in next-generation sequencing, the integration of artificial intelligence (AI) into digital pathology, the development of advanced mass spectrometry-based proteomics, improvements in ribonucleic acid biomarker detection technologies, and seamless integration with cloud-based data platforms.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27363&type=smp

What Are The Key Drivers Of Growth In The Next Generation Tissue Biomarkers Market?

The increasing demand for personalized medicine is projected to stimulate the growth of the next generation tissue biomarkers market moving forward. Personalized medicine refers to a medical methodology that customizes treatment strategies based on an individual’s genetic makeup, lifestyle, and environmental elements. The integration of personalized medicine is expanding due to ongoing progress in genomic technologies, which facilitate highly specific and individualized treatment plans. The call for personalized medicine is boosting the creation of next-generation tissue biomarkers, as these provide exact and tailored data essential for adapting treatments to each patient’s distinct tissue profile. For instance, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that in 2023, the FDA gave approval to 16 new personalized treatments for rare disease patients, an increase from six in 2022. The newly approved personalized treatments for 2023 also encompassed seven cancer drugs and three for other diseases and conditions. Therefore, the escalating need for personalized medicine is a primary force driving the growth of the next generation tissue biomarkers market.

What Are The Leading Segments Analyzed In The Next Generation Tissue Biomarkers Market?

The next generation tissue biomarkers market covered in this report is segmented

1) By Type: Genomic Biomarkers, Proteomic Biomarkers, Epigenetic Biomarkers, Transcriptomic Biomarkers, Metabolomic Biomarkers

2) By Technology: Immunohistochemistry, Next-Generation Sequencing, Mass Spectrometry (Ms)-Based Proteomics, Spatial Biology Platforms, Digital Pathology And Artificial Intelligence Analysis, Other Technologies

3) By Application: Oncology, Companion Diagnostics, Drug Discovery And Development, Neurology, Other Applications

4) By End Use: Hospitals And Reference Labs, Pharma And Biotech Companies, Academic And Research Institutes, Contract Research Organizations

Subsegments:

1) By Genomic Biomarkers: Single Nucleotide Polymorphisms, Copy Number Variations, Gene Fusions

2) By Proteomic Biomarkers: Protein Expression Levels, Post-Translational Modifications, Protein-Protein Interactions

3) By Epigenetic Biomarkers: Histone Modification Patterns, Chromatin Remodeling Biomarkers, Non-Coding Ribonucleic Acid Regulation

4) By Transcriptomic Biomarkers: Long Non-Coding Ribonucleic Acids, Circular Ribonucleic Acids, Alternative Splicing Variants

5) By Metabolomic Biomarkers: Lipid Profiles, Amino Acid Signatures, Organic Acids

What Are The Major Trends Driving The Growth Of The Next Generation Tissue Biomarkers Market?

Leading companies in the next generation tissue biomarkers market are concentrating on creating advanced solutions, including genomic-based diagnostic assays and sequencing solutions, with the aim of boosting the accuracy, speed, and personalization of cancer diagnosis and treatment. These genomic-based diagnostic assays and sequencing solutions involve tools and techniques that analyze genetic information to pinpoint disease-related biomarkers, thus allowing for more precise and individualized approaches to diagnosis and therapy. For instance, in August 2024, Illumina Inc., a US-based biotechnology company, obtained FDA approval for its TruSight Oncology Comprehensive test, along with two companion diagnostics, to quickly connect cancer patients with targeted therapies. This test profiles more than 500 genes from a single tissue sample, enabling precise treatment selection for various solid tumors. It automates biomarker detection and supports 24/7 deployment, notably reducing turnaround times and improving clinical efficiency, which signifies a modern method for streamlining cancer diagnostics within a regulated framework.

Who Are The Key Multinational Companies Dominating The Next Generation Tissue Biomarkers Market?

Major companies operating in the next generation tissue biomarkers market are Roche Diagnostics, Thermo Fisher Scientific Inc., LabCorp., Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Bio-Techne Corporation, Myriad Genetics Inc., NeoGenomics Laboratories Inc., Guardant Health Inc., Foundation Medicine Inc., NanoString Technologies Inc., PathAI Inc., Biocartis Group NV, Personalis Inc., Ultivue Inc., Indica Labs Inc., Strata Oncology Inc., Genialis Inc., Alida Biosciences Inc., and Biofidelity Ltd.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/next-generation-tissue-biomarkers-global-market-report

What Are The Regional Market Dynamics Impacting The Next Generation Tissue Biomarkers Industry?

North America was the largest region in the next generation tissue biomarkers market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next generation tissue biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Next Generation Tissue Biomarkers Market Report:

https://www.thebusinessresearchcompany.com/customise?id=27363&type=smp

Browse Through More Reports Similar to the Global Next Generation Tissue Biomarkers Market 2025, By The Business Research Company

Nail Care Products Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/nail-care-products-global-market-report

Nail Salon Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/nail-salon-global-market-report

Nail Polish Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/nail-polish-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795